ESCCA Industrial Partner Presentations & sponsor sessions and events

 

Overview per day

 

Wednesday 18 September

16.10-16.40

BD

ESCCA Industrial Partner Presentation

Thursday 19 September

12.00-12.30  

Beckman Coulter

ESCCA Industrial Partner Presentation

12.45

Beckman Coulter

Meet the Experts

13.00-13.30

Sysmex Europe

Lunch & Learn

15.15

Beckman Coulter

Meet the Experts

17.45-18.15

Sysmex Europe

Meet the Expert

17.30-18.30

Beckman Coulter  

Booth Reception - “Cytometry Slam”

17.30-18.30

BD

Panel session

Friday 20 September 

10.45

Beckman Coulter

Meet the Experts

Peer Gynt

11.00-11.20

Agilent

Corporate Lecture

Plenary room

12.45

Beckman Coulter

Meet the Experts

Peer Gynt

 

Overview per sponsor

 

Sysmex Europe

Thursday 19 September

13:00 - 13.30  Lunch & Learn (room Symfoni)
Title: Impact of Gating Variance on Flow Cytometry Data
Speaker: Liam Whitby, UK NEQUAS (Sheffield, UK)

17.45 - 18.15  Meet the Expert (room Symfoni)
Title: Towards reproducible clustering in clinical flow cytometry
Speaker: Tony Burpee, Applied Cytometry, Sheffield, UK

 

Beckman Coulter

Thursday, 19 September  

12.00 - 12.30  ESCCA Industrial Partner Presentation (Plenary room)
Speaker: Prof. Dr. Wolfgang Kern, Münchner Leukämielabor GmbH
Title: Flow cytometry and hematologic malignancies: On the road to new concepts – More colors, better detectors & automated analysis

12.45  Meet the Expert (room Peer Gynt)
Wolfgang Kern, Munich, Germany
Development of multi-color flow assays

17.30 - 18.30  Booth reception (booth PR1)
Speaker: Michael Kapinsky, Krefeld, Germany
Title: JK-36, a novel camelid-derived nanobody, enables uncompromised detection of Daratumumab-disguised CD38

15.45 - Meet the Expert (room Peer Gynt)
Andy Rawstron, Leeds, United Kingdom
Measurable residual disease in CLL: time for generation XX

 

Friday, 20 September

10.45  Meet the Expert (room Peer Gynt)
Matteo della Porta, Milano, Italy
Implications of ClearLLab 10C system in the diagnostic work up of patients with peripheral blood cytopenia

12.45 - Meet the Expert (room Peer Gynt)
Marianna Tzanoudaki, Athens, Greece
Can assay robustness replace standardization? First experiences with an SOP-free multicenter-multiplatform approach in immune deficiency screening

 

BD

Wednesday 18 September

16.10-16.40 - ESCCA Industrial Partner Presentation (Plenary room)
Title: An incredibly amazing experience… 
Speaker: Debbie Bruno - Ampath Laboratories, Pretoria, South Africa

17.30 - 18.30  Panel session (room Ibsen)
Title: IVDR implementation: the points of view of different stakeholders

 

Other sponsors

11.00 - 11.20  Agilent - Corporate Lecture (Plenary room)

Speaker: Tom Just, General Manager, Head of Reagent Partnership Division at Agilent Technologies Denmark.
Tom Just holds a Msc in Human Biology. In 1995 he began a career in Dako (now Agilent Technologies). Tom spent the first 6 years in Dako as a Research Scientist in flow cytometry, playing a key role in the development of the flow cytometry reagent portfolio, including the design of the Dako MultiMixTM flow cytometry panels and the Dako Telomere PNA kit for flow cytometry.
In 2002 Tom continued exploring and extending his knowledge within flow cytometry as a Director of Research in Dako. In 2005 he broadened his field of maneuver by including also the responsibility of primary antibodies. Tom then moved into more customer-oriented roles with responsibility for Scientific Support and Marketing and since 2016 he has held the position of General Manager, Head of Reagent Partnership Division at Agilent Technologies. Based on more than 25 years of interaction with commercial and private laboratories, Tom knows the importance of excellent product quality, delivery performance and customer support.
Description: Agilent became a player in the clinical flow cytometry market after acquisition of Dako in 2012. For several years and until today, Agilent has been a provider of reagents into the clinical labs, focusing on key and recognized products such as Kappa/Lambda and intracellular markers like MPO, Plasma Cell/VS38c and TdT.
With the acquisition of ACEA Biosciences in 2018, Agilent is now in an unprecedented position to offer broader flow solutions to its customers, including a wider portfolio of reagents and clinical flow cytometers with capability for processing up to 27 parameters.
The vision to provide complete workflow solutions within cancer diagnostics and becoming a key player in fighting cancer is one of Agilent’s main drivers, now moving one step forward by providing new flow cytometry alternatives to clinical labs worldwide.